Introduction
Roughly one-fourth of American adults smoke, and each of them faces increased risk of death or illness from cardiac and respiratory diseases, including cancer. But they also face the likelihood that they will fail in their attempt to quit smoking—relapse occurs in more than half of all quitting attempts within 6 months.
Discovery
During the Discovery section of the program, speakers addressed the most recent findings in the field of nicotinic receptor biology and CNS neurochemical systems— such as GABA and glutamate—that play a role in nicotine effects in the brain.
Smoking Cessation Pharmacotherapy: Accelerating Discovery-to-Delivery
Dr. William Corrigall, National Institute on Drug Abuse
Emerging Evidence for the Role of Polymorphic Drug Metabolizing Enzymes in Smoking and Behavior Treatment
Dr. Caryn Lerman, University of Pennsylvania and Dr. Rachel Tyndale, University of Toronto
Emerging Neuronal Nicotinic Receptor Targets
Dr. Marina Picciotto, Yale University School of Medicine
Smoking: Neurochemical Systems Beyond Dopamine
Dr. Julie Staley, Yale University School of Medicine
Synaptic Mechanisms Underlying Nicotine-Induced Excitation of Brain Reward Areas Dr. Daniel McGehee, University of Chicago
Development
The Development section of the program provided a background on the drug development process, presentations on emerging medications, such as antidepressants and nicotine vaccines, and an overview of medications in late-phase development.
Smoking Cessation Pharmacotherapy: Accelerating Discovery to Development, Medications Development Overview
Dr. Frank Vocci, National Institute on Drug Abuse
Recycling Psychiatric Medications for Smoking Cessation
Dr. John Hughes, University of Vermont
Industry Pipeline: Smoking Cessation Products
Dr. Charles Grudzinskas, Drug Development Consultant
Vaccines That Target Nicotine In the Blood
Dr. Paul Pentel, Hennepin County Medical Center
Delivery
Presentations on Delivery focused on strategies for developing widespread access and use of medications within the health care system and beyond.
Barriers to Delivery and Utilization of Current Tobacco Cessation Treatments
Dr. Scott Leischow, National Cancer Institute [slides not available]
Enhancing Public Health Impact By Increasing Use of Medications
Dr. Saul Shiffman, University of Pittsburgh and Pinney Associates
Challenges to Effective Medication Use
Dr. Richard Hurt, Mayo Clinic Nicotine Dependence Center
Models for Effective Medication Use in Health Care Systems
Dr. Susan Curry, University of Illinois at Chicago
|